Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Next Previous
X
Search
Trial Profile

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Sponsors CTI BioPharma

    • Most Recent Events

    • 12 Dec 2023 Results reporting rates of hematologic improvement in PLTs with pacritinib across PERSIST-2 and PAC203 clinical trial, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 15 Jun 2023 Results comparing Momelotinib vs Pacritinib for analyzing safety and anemia outcomes of MMB vs PAC via matching-adjusted indirect comparison of SIMPLIFY-1 , SIMPLIFY-2 , MOMENTUM and PERSIST-2, PAC203, presented at the 28th Congress of the European Haematology Association
    • 11 Dec 2022 Results published in the CTI Biopharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top